About: BMS-641988

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

BMS-641988 is a nonsteroidal antiandrogen which was developed by Bristol-Myers Squibb for the treatment of prostate cancer but was never marketed. It acts as a potent competitive antagonist of the androgen receptor (AR) (Ki = 10 nM; IC50 = 56 nM). The drug was found to have 20-fold higher affinity for the AR than bicalutamide in MDA-MB-453 cells, and showed 3- to 7-fold the antiandrogenic activity of bicalutamide in vitro. It may have some weak partial agonist activity at the androgen receptor. BMS-641988 is transformed by CYP3A4 into , and this metabolite is then reduced to by cytosolic reductases. All three compounds show similar antiandrogenic activity. In addition to its antiandrogenic activity, BMS-641988 shows activity as a negative allosteric modulator of the GABAA receptor, and ca

Property	Value
dbo:abstract	BMS-641988 is a nonsteroidal antiandrogen which was developed by Bristol-Myers Squibb for the treatment of prostate cancer but was never marketed. It acts as a potent competitive antagonist of the androgen receptor (AR) (Ki = 10 nM; IC50 = 56 nM). The drug was found to have 20-fold higher affinity for the AR than bicalutamide in MDA-MB-453 cells, and showed 3- to 7-fold the antiandrogenic activity of bicalutamide in vitro. It may have some weak partial agonist activity at the androgen receptor. BMS-641988 is transformed by CYP3A4 into , and this metabolite is then reduced to by cytosolic reductases. All three compounds show similar antiandrogenic activity. In addition to its antiandrogenic activity, BMS-641988 shows activity as a negative allosteric modulator of the GABAA receptor, and can produce seizures in animals at sufficiently high doses. It also shows some drug-induced QT prolongation. BMS-641988 reached phase I clinical trials prior to the discontinuation of its development. The clinical development of BMS-641988 was terminated due to the occurrence of a seizure in a patient during a phase I study. (en)
dbo:casNumber	1093276-09-5 573738-99-5
dbo:chEBI	95017
dbo:chEMBL	3932464
dbo:class	dbr:Nonsteroidal_antiandrogen
dbo:fdaUniiCode	W17M53Y8IM
dbo:pubchem	24768935
dbo:thumbnail	wiki-commons:Special:FilePath/BMS-641988.svg?width=300
dbo:wikiPageExternalLink	https://adisinsight.springer.com/drugs/800026026
dbo:wikiPageID	57708117 (xsd:integer)
dbo:wikiPageLength	6135 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1040539360 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Potency_(pharmacology) dbr:MDA-MB-453 dbr:Metabolite dbr:Partial_agonist dbr:Bicalutamide dbr:Androgen_receptor dbr:Cytosol dbr:In_vitro dbc:Abandoned_drugs dbc:GABAA_receptor_negative_allosteric_modulators dbc:Trifluoromethyl_compounds dbr:Competitive_antagonist dbr:Oral_administration dbr:Antiandrogen dbr:Clinical_trial dbr:Prostate_cancer dbr:Bristol-Myers_Squibb dbc:Hormonal_antineoplastic_drugs dbc:Imides dbc:Nonsteroidal_antiandrogens dbr:Cell_(biology) dbr:Drug-induced_QT_prolongation dbr:GABAA_receptor dbr:Reductase dbc:Prostate_cancer dbr:Redox dbc:Nitriles dbc:Sulfonamides dbr:Affinity_(pharmacology) dbr:Biotransformation dbr:CYP3A4 dbr:Seizure dbr:Phases_of_clinical_research dbr:Nonsteroidal_antiandrogen dbr:Negative_allosteric_modulator dbr:BMS-501949 dbr:BMS-570511
dbp:c	20 (xsd:integer)
dbp:casNumber	1093276 (xsd:integer)
dbp:casSupplemental	573738 (xsd:integer)
dbp:chebi	95017 (xsd:integer)
dbp:chembl	3932464 (xsd:integer)
dbp:class	dbr:Nonsteroidal_antiandrogen
dbp:f	3 (xsd:integer)
dbp:h	20 (xsd:integer)
dbp:iupacName	N-[-2-[4-cyano-3-phenyl]-4,7-dimethyl-1,3-dioxo-3a,5,6,7a-tetrahydro-octahydro-1H-4,7-epoxyisoindol-5-yl]ethanesulfonamide (en)
dbp:n	3 (xsd:integer)
dbp:o	5 (xsd:integer)
dbp:pubchem	24768935 (xsd:integer)
dbp:routesOfAdministration	dbr:Oral_administration
dbp:s	1 (xsd:integer)
dbp:smiles	CCSN[C@@H]1C[C@@]2C (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	HYNANJUKEMCYEQ-HIGHGGLBSA-N (en)
dbp:unii	W17M53Y8IM (en)
dbp:width	250 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Androgen_receptor_modulators dbt:Antineoplastic-drug-stub dbt:Drugbox dbt:Genito-urinary-drug-stub dbt:Reflist dbt:Abbrlink
dcterms:subject	dbc:Abandoned_drugs dbc:GABAA_receptor_negative_allosteric_modulators dbc:Trifluoromethyl_compounds dbc:Hormonal_antineoplastic_drugs dbc:Imides dbc:Nonsteroidal_antiandrogens dbc:Prostate_cancer dbc:Nitriles dbc:Sulfonamides
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment	BMS-641988 is a nonsteroidal antiandrogen which was developed by Bristol-Myers Squibb for the treatment of prostate cancer but was never marketed. It acts as a potent competitive antagonist of the androgen receptor (AR) (Ki = 10 nM; IC50 = 56 nM). The drug was found to have 20-fold higher affinity for the AR than bicalutamide in MDA-MB-453 cells, and showed 3- to 7-fold the antiandrogenic activity of bicalutamide in vitro. It may have some weak partial agonist activity at the androgen receptor. BMS-641988 is transformed by CYP3A4 into , and this metabolite is then reduced to by cytosolic reductases. All three compounds show similar antiandrogenic activity. In addition to its antiandrogenic activity, BMS-641988 shows activity as a negative allosteric modulator of the GABAA receptor, and ca (en)
rdfs:label	BMS-641988 (en)
owl:sameAs	wikidata:BMS-641988 https://global.dbpedia.org/id/2YYH8
prov:wasDerivedFrom	wikipedia-en:BMS-641988?oldid=1040539360&ns=0
foaf:depiction	wiki-commons:Special:FilePath/BMS-641988.svg
foaf:isPrimaryTopicOf	wikipedia-en:BMS-641988
is dbo:wikiPageRedirects of	dbr:C20H20F3N3O5S dbr:BMS-641,988 dbr:BMS641988 dbr:BMS_641,988 dbr:BMS_641988
is dbo:wikiPageWikiLink of	dbr:C20H20F3N3O5S dbr:Discovery_and_development_of_antiandrogens dbr:BMS-641,988 dbr:BMS641988 dbr:BMS_641,988 dbr:BMS_641988
is foaf:primaryTopic of	wikipedia-en:BMS-641988

This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License